0.82
+0.018(+2.25%)
Currency In GBp
Address
Alderley Park, Block 24
Nether Alderley, SK10 4TG
United Kingdom of Great Britain and Northern Ireland
Phone
44 16 2546 6591
Website
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
October 21, 2015
| Name | Title | Pay | Year Born |
| Dr. Huw Jones BSc, Ph.D. | Chief Executive Officer & Executive Director | 304,730 | 1959 |
| Mr. Toni Haenninen | Chief Financial Officer & Director | 0 | 1977 |
| Dr. Helen Kuhlman | Chief Business Officer | 0 | N/A |
| Dr. Glen Clack FFPM, M.D. | Chief Medical Officer | 0 | N/A |
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.